Research progress on biomarkers of pulmonary embolism

Yang, Pengbo; Li, Hexin; Zhang, Junhua; Xu, Xiaomao

doi:10.1111/crj.13414

Cited by 10 publications

(9 citation statements)

References 81 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apelin, fibulins, haemopexin, a2-macroglobulin, Ig a1-chain C region, TNF-α, HMGB1, neutrophil-to-lymphocyte ratio and albumin are among the other biomarkers whose effectiveness has been investigated in the diagnosis of pulmonary embolism [21][22][23][24][25][26]. miRNA studies on this subject have stated that these new methods and technologies can be deployed to discover new specific clinical diagnosis and risk stratification biomarkers, diagnostic schedules, and treatment protocols for pulmonary embolism [27,28]. In our study, the relationship between adropin and PE was investigated (Fig.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of adropin as a preliminary test to exclude acute pulmonary embolism: a prospective study

et al. 2022

View full text Add to dashboard Cite

Background This study aims to investigate the diagnostic accuracy of adropin as a biomarker to exclude the diagnosis of acute pulmonary embolism (PE). Methods Patients admitted to the emergency department of a tertiary health centre between August 2019 and August 2020 and diagnosed with PE were included in this prospective cohort study. The amount of serum adropin was determined in patients with (PE) and compared with that of healthy volunteers. Receiver operating characteristic analysis was performed with the obtained data, and the area under the curve (AUC) with a 95% confidence interval was determined. The parameters of diagnostic accuracy for PE were determined. Results A total of 57 participants were included in the study (28 controls and 29 PE patients). The mean adropin level in the PE group was 187.33 ± 62.40 pg/ml, which was significantly lower than that in the control group (524.06 ± 421.68 pg/ml) (p < 0.001). When the optimal adropin cut-off value was 213.78 pg/ml, the likelihood ratio of the adropin test was 3.4, and the sensitivity of the adropin test at this value was 82% with specificity of 75% (95% CI; AUC: 0.821). Conclusion Our results suggest that adropin may be considered for further study as a candidate marker for the exclusion of the diagnosis of PE. However, more research is required to verify and support the generalizability of our study results.

show abstract

Section: Discussionmentioning

confidence: 99%

Diagnostic accuracy of adropin as a preliminary test to exclude acute pulmonary embolism: a prospective study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, the literature lacks studies evaluating the use of biomarkers in the context of PI diagnosis [ 43 ]. Similarly, the increase in inflammatory biomarkers, which could be secondary to numerous other pathological conditions, is not particularly informative but opens prospects for prognostic evaluation in the context of PI [ 45 , 46 ].…”

Section: Possible Diagnostic Criteriamentioning

confidence: 99%

Pulmonary Embolism Presenting with Pulmonary Infarction: Update and Practical Review of Literature Data

Gagno

Padoan

D’Errico

et al. 2022

JCM

View full text Add to dashboard Cite

Pulmonary infarction (PI) is a possible consequence of pulmonary embolism (PE). The real incidence of PI could be underestimated considering only non-fatal PE presentation. However, following postmortem examination, the prevalence of PI is considerably higher. This evidence suggests the necessity of proper diagnostic protocol for identifying PI. Unfortunately, PI diagnosis can sometimes be challenging, due to the overlapping of symptoms with other diseases. Nowadays, the diagnosis is mainly based on radiological evaluation, although the combination with emerging imaging techniques such as ultrasound and nuclear scanning might improve the diagnostic algorithm for PI. This review aims to summarize the available data on the prevalence of PI, the main predisposing factors for the development of PI among patients with PE, to resume the possible diagnostic tools, and finally the clinical and prognostic implications.

show abstract

“…In clinical studies, lung cancer is an important risk factor for PE [4], with a combined probability of approximately 3.7%. In the conventional approach, lung cancer combined with pulmonary embolism is determined according to the Chinese Society of Respiratory Medicine [5].…”

Section: Introductionmentioning

confidence: 99%

Digital-Twin-Enabled IoMT System for Surgical Simulation Using rAC-GAN

Tai

Zhang

et al. 2022

IEEE Internet Things J.

View full text Add to dashboard Cite

A digital twin-enabled Internet of Medical Things (IoMT) system for telemedical simulation is developed, systematically integrated with mixed reality (MR), 5G cloud computing, and a generative adversarial network (GAN) to achieve remote lung cancer implementation. Patient-specific data from 90 lung cancer with pulmonary embolism (PE)-positive patients, with 1372 lung cancer control groups, were gathered from Qujing and Dehong, and then transmitted and preprocessed using 5G. A novel robust auxiliary classifier generative adversarial network (rAC-GAN)-based intelligent network is employed to facilitate lung cancer with the PE prediction model. To improve the accuracy and immersion during remote surgical implementation, a real-time operating room perspective from the perception layer with a surgical navigation image is projected to the surgeon's helmet in the application layer using the digital twin-based MR guide clue with 5G. The accuracies of the area under the curve (AUC) of our new intelligent IoMT system were 0.92, and 0.93. Furthermore, the pathogenic features learned from our rAC-GAN model are highly consistent with the statistical epidemiological results. The proposed intelligent IoMT system generates significant performance improvement to process substantial clinical data at cloud centers and shows a novel framework for remote medical data transfer and deep learning analytics for digital twin-based surgical implementation.

show abstract

Research progress on biomarkers of pulmonary embolism

Cited by 10 publications

References 81 publications

Diagnostic accuracy of adropin as a preliminary test to exclude acute pulmonary embolism: a prospective study

Diagnostic accuracy of adropin as a preliminary test to exclude acute pulmonary embolism: a prospective study

Pulmonary Embolism Presenting with Pulmonary Infarction: Update and Practical Review of Literature Data

Digital-Twin-Enabled IoMT System for Surgical Simulation Using rAC-GAN

Contact Info

Product

Resources

About